CPCasey N. Pinto

Casey N. Pinto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Casey N. Pinto has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Training healthcare providers in adolescent alcohol and substance use screening through project ECHO in rural Pennsylvania: A brief case report

    by Uttara Seshu, Jessica S. Beiler, Sarah Cichy, Erik Lehman, Julie Lentes, Jennifer Kraschnewski, Casey N. Pinto

  • Open Access

    Distinguishing active HIV-1 infection from vaccine-induced seropositivity in HIV vaccine trial participants

    by Ketan Dighe, Oguzhan Colak, Parikshit Moitra, Maha Alafeef, David Skrodzki, Teresea Aditya, Pranay Saha, Nivetha Gunaseelan, John Hural, Casey Pinto, et al.

    Vaccine-induced seropositivity (VISP) causes antibodies produced by HIV-1 vaccines to react with standard serological tests, complicating diagnosis and leading to false positives. To distinguish VISP from true HIV infections, we developed a rapid, multiplexed companion electrochemical assay that integrates a three-dimensional–printed device with screen-printed electrodes coated with antigen, antibody, and methylene blue–labeled antisense oligonucleotide probes. The test delivers quantitative results within 5 minutes with calculated analytical limits of detection of 5.88 picograms per milliliter for p24 antigen, 10.96 picograms per milliliter for anti-p24 antibody, and 1259 copies per milliliter for HIV-1 RNA, with minimal cross-reactivity. Clinical testing with 104 plasma samples obtained from vaccinated/unvaccinated, HIV-positive/negative individuals demonstrated 95% sensitivity and 98% specificity in distinguishing active HIV-1 infection from VISP cases. Receiver operating characteristic analysis produced area under the curve values of 0.9888 for HIV-1 RNA, 0.9705 for anti-p24 antibody, and 0.9356 for p24 antigen. These findings highlight the potential to reduce false-positive results caused by VISP by integrating this diagnostic test in clinical trials and large-scale vaccination programs.


  • Open Access

    ViraLite: An Ultracompact HIV Viral Load Self-Testing System with Internal Quality Control

    by Anthony J Politza, Tianyi Liu, Aneesh Kshirsagar, Ming Dong, Ahasan Ahamed, Muhammad Asad Ullah Khalid, Roland Jones, Uttara Seshu, Kathryn Risher, Casey N Pinto, et al.

    The availability of effective antiretroviral therapy has made HIV manageable, provided patients have consistent access to routine viral load (VL) testing. Nonetheless, access to frequent VL testing remains limited. There is a need for accessible, user-friendly testing systems that allow people living with HIV (PLHIV) to monitor their VL more frequently and empower self-management. Here, we developed ViraLite, a sample-to-answer, compact, accessible, and battery-powered system for HIV viral load monitoring. The system is built upon a probe-based RT-LAMP assay that allows for multiplexed detection and quantification. An internal quality control targeting the RNase P was incorporated to enhance the reliability of the results. A software-reconfigurable real-time sensing system empowered by machine learning and a smartphone-guided protocol was developed in tandem to analyze the multiplexed assay. We analyzed 45 clinically archived samples using ViraLite and benchmarked our results against qRT-PCR, which showed 21 positive and 23 negative samples. Using our process control, ViraLite first identified 17 inconclusive samples that would otherwise be classified as negative. Then, ViraLite classified 14 out of 15 HIV-positive samples (93.3%) and 13 out of 13 HIV-negative samples (100%). The incorporation of RNase P as a process control increased the sensitivity of ViraLite from 66.66% to 93.33%, while maintaining a high specificity (100%). To assess the acceptance of ViraLite among PLHIV, we recruited 480 participants from online and three clinical sites to complete a survey. Over 86% of participants indicated ViraLite had benefits in convenience and privacy, on the other hand 61% of participants indicated concerns with test accuracy. The integration of compact hardware, a reliable assay, and smartphone guidance provides an accurate, easy to use system for PLHIV to self-manage their viral load and update their prescriptions frequently.

  • Open Access

    Use of telehealth by US adults with depression or anxiety disorder: Results from 2022 Health Information National Trends Survey

    by Pu Bai, Emily Brignone, Bibo Jiang, Casey Pinto, Li Wang

    Background: Telehealth use has significantly increased recently. However, little is known about its use by individuals with depression or anxiety disorders. This study aims to explore the patterns of telehealth use among those individuals. Methods: Data used were from the 2022 Health Information National Trends Survey (HINTS) cycle 6. Weighted logistic regression was performed to test the association between depression/anxiety disorder and telehealth use, and to explore reasons for using/not using telehealth among those with depression/anxiety, compared to those without. Results: Out of the 4952 study participants, 2887 (weighted percentage: 39.36%) had used telehealth in the past 12 months. Those with depression/anxiety disorder had significantly higher telehealth use, compared to those without (57% vs. 32%; OR = 2.65; 95% CI: (2.04, 3.43)). Factors affecting telehealth use could differ by depression/anxiety disorder status. Among those with depression/anxiety disorder, being woman or married was not associated with telehealth use, whereas they were significant factors among those without depression/anxiety disorder. Among those with depression/anxiety, non-Hispanic Black participants (OR = 0.51; CI: (0.78, 0.94)) were less likely to use telehealth, compared to non-Hispanic White participants; additionally, higher income was associated with telehealth use. Regarding reasons for using telehealth, convenience (OR = 1.80; CI: (1.21, 2.68)) and avoiding COVID infection (OR = 1.40; CI: (1.06, 1.86)) were more likely considered by those with depression/anxiety disorder. Conclusion: Individuals with depression/anxiety disorder were more likely to use telehealth and to do so for reasons of convenience and avoiding infection. Promoting telehealth to those with depression/anxiety disorder should consider their unique utilization patterns.


  • Congenital Syphilis in the US: A Narrative Review

    by Mahmoud M. Azqul, Stacey B. Griner, Casey N. Pinto

    Congenital syphilis (CS) continues to pose a significant global challenge. There has been a marked increase in reported cases in the United States, with 102.5 cases per 100,000 live births in 2022 compared with 11.6 cases per 100,000 live births in 2014. Congenital syphilis can lead to a range of severe complications, including premature birth, intrauterine growth restriction, miscarriage, perinatal death, stillbirth, and postnatal complications that may persist into later life. Maternal/parental factors such as age, race/ethnicity, occupation, income level, access to health care services, and incarceration have been linked to higher rates of CS. In addition, pregnant individuals who engage in high-risk behaviors such as sex work, having multiple sexual partners, or substance use are at a higher risk of exposure and subsequent infection. Routine screening for syphilis during pregnancy is crucial for its detection, timely management, and prevention of CS. The asymptomatic nature of the latent stage of syphilis further underscores the importance of prenatal syphilis screening. Studies in various countries have shown that early or first antenatal care visit screening for CS is cost-effective. This review article critically evaluates the current knowledge of CS in the United States, including its prevalence, social determinants of health, prevention efforts, challenges, the significance of screening, and the call to action to address the rising trend. (See Graphical Abstract)


  • Open Access

    Association between self-reported STI symptoms and stillbirth in sub-Saharan Africa using nationally representative household surveys

    by Skylar Pulver, Casey N. Pinto, Djibril M. Ba, Kathryn A. Risher

    Stillbirths are a known outcome of untreated sexually transmitted infections (STIs). Sub-Saharan Africa (SSA) shares a disproportionate burden of both stillbirths (2015: 29/1000 births vs 3/1000 births in high income countries globally) and STIs. Nationally representative survey data can inform stillbirth prevention measures in multiple countries in the SSA region, with greater generalizability than clinic-based studies. We assessed the association between any self-reported STI symptoms (STI diagnosis, abnormal genital discharge, genital sore or ulcer) in the last 12 months and stillbirth in the prior five years, among women aged 15-49 years participating in nationally representative Demographic and Health Surveys (DHS) in 19 countries in SSA between 2015-2021 and reporting a pregnancy in the five years prior to interview. We used multivariable logistic regression models adjusting for maternal age, wealth index, education level of mother, cigarette smoking behaviors, health care utilization and country of residence. Among 160,995 SSA women who reported being pregnant at least once between 2011-2021, 18.0% (25,596) reported any STI symptom in the prior year and 1.9% (3,205) reported a stillbirth in the past five years. Women who self-reported STI symptoms in the past year had 1.30 (95% CI 1.16-1.47) times the odds of stillbirth in the prior five years compared to women who did not report STI symptoms. Women 35-49 years old had 1.17 (95% CI 1.04-1.33) times the odds of stillbirth compared to those 15-24 years old. The association found between self-reported STI symptoms and stillbirth highlights the need for increased screening for STI symptoms and subsequent treatment among pregnant women in SSA.